Company Profile
Ipsen S.A., a biopharmaceutical company develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience globally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications.
Its portfolio also includes Dysport for motor muscular disorders and medical aesthetics indications, and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy.
It also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors. Its portfolio also includes Onivyde for second-line metastatic pancreatic cancer, and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome.
Additionally, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis. Its portfolio also includes Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva, and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications.
It also develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications. Its portfolio also includes Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications, IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications, and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Founded in 1929, Ipsen is headquartered in Paris, France.